Timeline Wins $5.3M Judgment Against Fake Urolithin A Sellers

If you bought a urolithin A supplement online in the last year without checking the seller carefully, there’s a real chance you paid for a product that contained none of the ingredient on its label.

What Happened

Timeline, the Swiss longevity company behind the Mitopure urolithin A brand, won a $5.3 million judgment and permanent injunctions against 19 online sellers who marketed counterfeit and mislabeled urolithin A products. The case, decided by default judgment in the US District Court for the District of Massachusetts, originally named 30 defendants when filed in October 2025; 11 settled before judgment. Testing showed the sellers’ products either contained no urolithin A at all or substantially less than what the label claimed, alongside unauthorized use of the Mitopure trademark, fabricated third-party testing claims, fake manufacturing information, and undisclosed filler ingredients.

Timeline cofounder and president Chris Rinsch framed the stakes for the company directly: “Timeline has invested over 18 years and more than $50 million USD building the clinical evidence for our proprietary Mitopure.” That evidence base — reported to include more than five clinical trials and dozens of patents behind the compound — is the thing counterfeit sellers were riding on without paying for or replicating.

Why It Matters

Urolithin A is a postbiotic compound studies have linked to mitochondrial function, and it’s one of the more heavily marketed ingredients in the longevity supplement space precisely because Timeline’s clinical research gave it credibility. That credibility is also what made it a counterfeiting target: sell a capsule that looks identical to a well-researched product, skip the actual ingredient, and pocket the difference. Buyers had no easy way to tell the difference from the packaging alone — the fraud only surfaces under lab testing, which is exactly what this case relied on.

What This Means for Builders

For a market built on clinical evidence rather than folklore, unenforced counterfeiting is an existential risk — every fake bottle sold under a legitimate brand’s name erodes the trust that brand spent years and millions of dollars establishing. A $5.3 million judgment with permanent injunctions is a meaningfully higher deterrent than a quiet takedown request, and it signals that legitimate longevity brands are now willing to litigate counterfeiting as aggressively as any consumer packaged goods company would. For buyers, the practical takeaway is narrower and more useful: buy urolithin A and similar clinically-branded compounds directly from the manufacturer or their verified retail listings, not from unfamiliar third-party marketplace sellers offering a lower price on an identical-looking bottle.

Source: Longevity.Technology

Content created with AI assistance and reviewed for accuracy.